Menopause
Bradley Pharmaceuticals Announces Launch of Elestrin
Published in Medical Letter on the CDC and FDA, July 1st, 2007
Bradley Pharmaceuticals, Inc. (NYSE:BDY) announced the launch of Elestrin(TM) (estradiol gel 0.06%) by the Company's Kenwood Therapeutics Division. Elestrin(TM) is an effective, low dose transdermal estrogen therapy that was approved by the Food and Drug Administration (FDA) in December 2006 for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Bradley in-licensed the product from BioSante Pharmaceuticals (AMEX:BPA) late last year and has exclusive marketing rights for Elestrin(TM) in the U.S. Elestrin(TM) is patent protected until 2022.
There are approximately 14,000 OB/GYN physicians in the U.S. who account for the majority of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Alzheimer Disease
Early results from Alzheimer's neuroimaging studies could speed research - Bird Flu
Avian influenza is on people's minds - Ear Disease
Skystar Receives Approval for 36 New Veterinary Medicines - Fibromyalgia
Gabapentin shown effective for fibromyalgia pain - Weight Loss
Does OTC diet pill Alli live up to its name? - Adverse Drug Reactions
Center for Molecular Medicine First Midwest-Based Lab Offering Roche Test to Help Predict Drug Performance & Improve Safety - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
